• Alexion Pharmaceuticals Inc., of Cheshire, Conn., posted higher-than-expected Soliris (eculizumab) sales of $400.4 million for the third quarter, up 36 percent year over year. Analyst estimates had predicted sales of $395 million. The company attributed the growth to steady additions of new patients with paroxysmal nocturnal hemoglobinuria and increasing numbers of new patients with atypical hemolytic uremic syndrome beginning Soliris treatment in the U.S. and Europe.